See the DrugPatentWatch profile for cosentyx

Cosentyx (secukinumab) is a human monoclonal antibody used to treat various inflammatory diseases such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It works by inhibiting interleukin-17A, a cytokine involved in inflammatory and immune responses [1].

According to DrugPatentWatch.com, there is currently no direct information available on how Cosentyx impacts live vaccine potency [2]. However, it is generally recommended that live vaccines should be administered before starting biologic therapy, including Cosentyx, due to the potential impact of these medications on the immune system [3][4]. This is because biologic therapies, like Cosentyx, can affect the body's ability to mount an immune response to vaccines, including live vaccines [3][4].

Inactivated or non-live vaccines, on the other hand, can generally be given safely during biologic therapy [3][4]. Nonetheless, it is important to consult with a healthcare provider to determine the most appropriate vaccination schedule, considering the individual's medical history and current treatment plan [3][4].

In summary, while there is no specific information on Cosentyx's impact on live vaccine potency, it is generally advised to administer live vaccines before starting biologic therapy due to the potential effects of these medications on the immune system.

Sources:
[1] Novartis. (2021). Cosentyx (secukinumab). Retrieved from <https://www.novartis.com/our- medicines/treatments/rheumatology/cosentyx>
[2] DrugPatentWatch.com. (n.d.). Secukinumab. Retrieved from <https://www.drugpatentwatch.com/drugs/secukinumab>
[3] Centers for Disease Control and Prevention. (2016). General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Retrieved from <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html>
[4] American College of Rheumatology. (2017). 2017 Guideline for the Treatment of Rheumatoid Arthritis. Retrieved from <https://www.rheumatology.org/Portals/0/Files/2017-Rheumatoid-Arthritis-Guideline.pdf>